Navin K. Kapur, MD, FSCAI, FAHA, FACC

Dr. Navin Kapur joined Abiomed in 2025 as chief medical and scientific officer, bringing extensive expertise in the field of cardiology and a commitment to advancing healthcare innovation.

Prior to joining Abiomed, Dr. Kapur was a professor at Tufts University School of Medicine in Boston, where he established himself as one of the most accomplished practitioners, scientists, and trialists in the field of cardiology. He is the founder of the Cardiogenic Shock Working Group, board-certified in interventional cardiology and advanced heart failure, and globally recognized as a leading expert in acute mechanical circulatory support, cardiogenic shock, the science of cardiac unloading and the biological response of Impella^® heart pumps.

Dr. Kapur’s clinical expertise includes advanced invasive hemodynamics, complex coronary intervention, mechanical circulatory support, and interventional therapies for advanced heart failure patients. He is the founding director of the Robert Kung combined Interventional Heart Failure fellowship program and served on multiple committees with organizations such as the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, the International Society for Heart and Lung Transplantation, and the Society for Cardiac Angiography and Interventions. He is an elected member of prestigious academic groups including the Association of University Cardiologists and the American Society of Clinical Investigators.

At Tufts University School of Medicine, he was the executive director of the Cardiovascular Center for Research and Innovation. As director of the Interventional Research Laboratories at Tufts Medical, Dr. Kapur conducted translational research addressing acute and chronic heart failure, and cardioprotective mechanisms during acute myocardial infarction. Dr. Kapur is the inventor of numerous patents and has extensive experience with device development. His leading hypothesis on mechanically unloading the heart has the potential to shift paradigms in acute heart attack therapy, aiming to mitigate ischemic heart failure and promote adaptive cardiac remodeling.

Additionally, as director of the Cardiac Biology Research Center within the Molecular Cardiology Research Institute at Tufts Medical Center, Dr. Kapur’s laboratory focused on molecular mechanisms of maladaptive cardiac remodeling, particularly regarding the transforming growth factor beta (TGFb) signaling pathway. His work highlighted the role of the TGFb receptors endoglin and bone morphogenetic protein-9, demonstrating potential therapeutic strategies for improving survival and reducing adverse cardiac remodeling in heart failure and pulmonary hypertension.